Literature DB >> 11728340

Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein.

T E Morrison1, A Mauser, A Wong, J P Ting, S C Kenney.   

Abstract

Viruses have evolved elaborate mechanisms to target many aspects of the host's immune response. The cytokine IFN-gamma plays a central role in resistance of the host to infection via direct antiviral effects as well as modulation of the immune response. In this study, we demonstrate that the Epstein-Barr virus (EBV) immediate-early protein, BZLF1, inhibits the IFN-gamma signaling pathway. BZLF1 decreases the ability of IFN-gamma to activate a variety of important downstream target genes, such as IRF-1, p48, and CIITA, and prevents IFN-gamma-induced class II MHC surface expression. Additionally, BZLF1 inhibits IFN-gamma-induced STAT1 tyrosine phosphorylation and nuclear translocation. Finally, we demonstrate that BZLF1 decreases expression of the IFN-gamma receptor, suggesting a mechanism by which EBV may escape antiviral immune responses during primary infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728340     DOI: 10.1016/s1074-7613(01)00226-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  55 in total

1.  The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression.

Authors:  Vivian Ruvolo; Lorena Navarro; Clare E Sample; Michael David; Seung Sung; Sankar Swaminathan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  The Epstein-Barr virus immediate-early protein BZLF1 induces both a G(2) and a mitotic block.

Authors:  Amy Mauser; Elizabeth Holley-Guthrie; Dennis Simpson; William Kaufmann; Shannon Kenney
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

4.  Amino acids in the basic domain of Epstein-Barr virus ZEBRA protein play distinct roles in DNA binding, activation of early lytic gene expression, and promotion of viral DNA replication.

Authors:  Lee Heston; Ayman El-Guindy; Jill Countryman; Charles Dela Cruz; Henri-Jacques Delecluse; George Miller
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 5.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

7.  Simian varicella virus inhibits the interferon gamma signalling pathway.

Authors:  Werner J D Ouwendijk; Suzanne van Veen; Ravi Mahalingam; Georges M G M Verjans
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

8.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 9.  Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity.

Authors:  Martin Rowe; Jianmin Zuo
Journal:  Microbes Infect       Date:  2010-02-01       Impact factor: 2.700

10.  The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation.

Authors:  K M Shah; S E Stewart; W Wei; C B J Woodman; J D O'Neil; C W Dawson; L S Young
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.